URGN FY 2017 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena

URGNUroGen Pharma Ltd.

$918M

FY 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M-53.5% YoY

Gross Profit

$8M92.6% margin

Operating Income

-$20M-244.5% margin

Net Income

-$20M-245.2% margin

EPS (Diluted)

$-2.06

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$10M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$76M

Total Liabilities

$7M

Stockholders' Equity

$69M

Cash & Equivalents

$37M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$18M	-53.5%
Gross Profit	$8M	$18M	-56.8%
Operating Income	-$20M	$798,000	-2600.0%
Net Income	-$20M	-$2M	-930.4%